Share This Article:

Management of Hepatocellular Carcinoma: Updated Review

Abstract Full-Text HTML XML Download Download as PDF (Size:218KB) PP. 536-545
DOI: 10.4236/jct.2013.42067    5,419 Downloads   8,002 Views   Citations


Hepatocellular carcinoma (HCC) represents one of the most challenging potentially curable tumors with high incidence, prevalence and mortality rates. For proper assessment, prognosis estimation and treatment decisions, at least seven important guidelines and staging systems were designated. Proper treatment needs the interaction of multidisciplinary HCC clinic to choose the most appropriate line of treatment. The different modalities of management include resection (surgery or transplantation), local ablation, chemoembolization, radioembolization and molecular targeted therapies with a wide range of investigational drugs that developed after the FDA approved sorafenib. Downstaging and bridging are two important strategies to manage HCC patients who will undergo liver transplantation to improve their postoperative survival. Finally, survival and prognosis depends on several prognostic factors that are either patient related or tumor related. In our study, we aim to provide an updated comprehensive review of the different aspects of liver cancer management starting from staging systems to the different applied treatment modalities.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

T. Elbaz, M. Kassas and G. Esmat, "Management of Hepatocellular Carcinoma: Updated Review," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 536-545. doi: 10.4236/jct.2013.42067.


[1] International Agency for Research on Cancer, 2011.
[2] R. Masuzaki, H. Yoshida, R. Tateishi, et al., “Staging Systems: Is There a Surgical Staging and a Medical One? Hepatologist’s Perspective,” Journal of Hepato-BiliaryPancreatic Sciences, Vol. 17, No. 4, 2010, pp. 440-442. doi:10.1007/s00534-009-0240-1
[3] J. N. Vauthey, G. Y. Lauwers, N. F. Esnaola, et al., “Simplified Staging for Hepatocellular Carcinoma,” Journal of Clinical Oncology, Vol. 20, No. 6, 2002, pp. 1527-1536. doi:10.1200/JCO.20.6.1527
[4] W. Lu, J. Dong, Z. Huang, et al., “Comparison of Four Current Staging Systems for Chinese Patients with Hepatocellular Carcinoma Undergoing Curative Resection: Okuda, CLIP, TNM and CUPI,” Journal of Gastroenterology and Hepatology, Vol. 23, No. 12, 2008, pp. 1874-1878. doi:10.1111/j.1440-1746.2008.05527.x
[5] K. Okuda, T. Ohtsuki, H. Obata, et al., “Natural History of Hepatocellular Carcinoma and Prognosis in Relation to Treatment. Study of 850 Patients,” Cancer, Vol. 56, No. 4, 1985, pp. 918-928. doi:10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E
[6] CLIP Investigators, “A New Prognostic System for Hepatocellular Carcinoma: A Retrospective Study of 435 Patients: The Cancer of the Liver Italian Program (CLIP) Investigators,” Hepatology, Vol. 28, No. 3, 1998, pp. 751-755. doi:10.1002/hep.510280322
[7] I. Levy, M. Sherman and Liver Cancer Study Group of the University of Toronto, “Staging of Hepatocellular Carcinoma: Assessment of the CLIP, Okuda, and ChildPugh Staging Systems in a Cohort of 257 Patients in Toronto,” Gut, Vol. 50, No. 6, 2002, pp. 881-885. doi:10.1136/gut.50.6.881
[8] C. Y. Hsu, C. Y. Hsia, Y. H. Huang, et al., “Selecting an Optimal Staging System for Hepatocellular Carcinoma: Comparison of 5 Currently Used Prognostic Models,” Cancer, Vol. 116, No. 12, 2010, pp. 3006-3014. doi:10.1002/cncr.25044
[9] C. Y. Lin, K. M. Kee, J. H. Wang, et al., “Is the Cancer of the Liver Italian Program System an Adequate Weighting for Survival of Hepatocellular Carcinoma? Evaluation of Intrascore Prognostic Value among 36 Subgroups,” Liver International, Vol. 29, No. 1, 2009, pp. 74-81. doi:10.1111/j.1478-3231.2008.01702.x
[10] S. Chevret, J. C. Trinchet, D. Mathieu, et al., “A New Prognostic Classification for Predicting Survival in Patients with Hepatocellular Carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire,” Journal of Hepatology, Vol. 31, No. 1, 1999, pp. 133-141. doi:10.1016/S0168-8278(99)80173-1
[11] T. W. Leung, A. M. Tang, B. Zee, et al., “Construction of the Chinese University Prognostic Index for Hepatocellular Carcinoma and Comparison with the TNM Staging System, the Okuda Staging System, and the Cancer of the Liver Italian Program Staging System: A Study Based on 926 Patients,” Cancer, Vol. 94, No. 6, 2002, pp. 1760-1769. doi:10.1002/cncr.10384
[12] F. D. Huitzil-Melendez, M. Capanu, E. M. O’Reilly, et al., “Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?” Journal of Clinical Oncology, Vol. 28, No. 17, 2010, pp. 2889-2895. doi:10.1200/JCO.2009.25.9895
[13] M. Kudo, H. Chung and Y. Osaki, “Prognostic Staging System for Hepatocellular Carcinoma (CLIP Score): Its Value and Limitations, and a Proposal for a New Staging System, the Japan Integrated Staging Score (JIS Score),” Journal of Gastroenterology, Vol. 38, No. 3, 2003, pp. 207-215. doi:10.1007/s005350300038
[14] M. Kudo, “Real Practice of Hepatocellular Carcinoma in Japan: Conclusions of the Japan Society of Hepatology 2009 Kobe Congress,” Oncology, Vol. 78, No. 1, 2010, pp. 180-188. doi:10.1159/000315740
[15] J. M. Llovet, C. Brú and J. Bruix, “Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification,” Seminars in Liver Disease, Vol. 19, No. 3, 1999, pp. 329-338. doi:10.1055/s-2007-1007122
[16] J. Bruix, M. Sherman, Practice Guidelines Committee and American Association for the Study of Liver Diseases, “Management of Hepatocellular Carcinoma,” Hepatology, Vol. 42, No. 5, 2005, pp. 1208-1236. doi:10.1002/hep.20933
[17] J. Guy, R. K. Kelley, J. Roberts, et al., “Multidisciplinary Management of Hepatocellular Carcinoma,” Clinical Gastroenterology and Hepatology, Vol. 10, No. 4, 2012, pp. 354-362. doi:10.1016/j.cgh.2011.11.008
[18] A. O. Kaseb, Y. M. Abaza and R. E. Roses, “Multidisciplinary Management of Hepatocellular Carcinoma,” Recent Results in Cancer Research, Vol. 190, 2013, pp. 247-259. doi:10.1007/978-3-642-16037-0_16
[19] R. G. Gish, R. Lencioni, A. M. Di Bisceglie, et al., “Role of the Multidisciplinary Team in the Diagnosis and Treatment of Hepatocellular Carcinoma,” Expert Review of Gastroenterology & Hepatology, Vol. 6, No. 2, 2012, pp. 173-185. doi:10.1586/egh.11.105
[20] V. Mazzaferro, S. Bhoori, C. Sposito, et al., “Milan Criteria in Liver Transplantation for HCC: An EvidenceBased Analysis on 15 Years of Experience,” Liver Transplantation, Vol. 17, No. 2, 2011, pp. S44-S57. doi:10.1002/lt.22365
[21] V. Mazzaferro, E. Regalia, R. Doci, et al., “Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis,” The New England Journal of Medicine, Vol. 334, No. 11, 1996, pp. 693-699. doi:10.1056/NEJM199603143341104
[22] F. Y. Yao, L. Xiao, N. M. Bass, et al., “Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF-Expanded Criteria Based on Preoperative Imaging,” American Journal of Transplantation, Vol. 7, No. 11, 2007, pp. 2587-2596. doi:10.1111/j.1600-6143.2007.01965.x
[23] P. A. Clavien, M. Lesurtel, P. M. Bossuyt, et al., “Recommendations for Liver Transplantation for Hepatocellular Carcinoma: An International Consensus Conference Report,” The Lancet Oncology, Vol. 13, No. 1, 2012, pp. e11-e22. doi:10.1016/S1470-2045(11)70175-9
[24] S. Padma, J. B. Martinie and D. A. Iannitti, “Liver Tumor Ablation: Percutaneous and Open Approaches,” Journal of Surgical Oncology, Vol. 100, No. 8, 2009, pp. 619-634. doi:10.1002/ jso.21364
[25] R. Lencioni, “Loco-Regional Treatment of Hepatocellular Carcinoma,” Hepatology, Vol. 52, No. 2, 2010, pp. 762-773. doi:10.1002/hep.23725
[26] R. Lencioni, C. Bartolozzi, D. Caramella, et al., “Treatment of Small Hepatocellular Carcinoma with Percutaneous Ethanol Injection. Analysis of Prognostic Factors in 105 Western Patients,” Cancer, Vol. 76, No. 10, 1995, pp. 1737-1746. doi:10.1002/1097-0142(19951115)76:10<1737::AID-CNCR2820761010>3.0.CO;2-P
[27] F. Brunello, A. Veltri, P. Carucci, et al., “Radiofrequency Ablation versus Ethanol Injection for Early Hepatocellular Carcinoma: A Randomized Controlled Trial,” Scandinavian Journal of Gastroenterology, Vol. 43, No. 6, 2008, pp. 727-735. doi:10.1080/00365520701885481
[28] K. Takayasu, S. Arii, I. Ikai, et al., “Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 Patients,” Gastroenterology, Vol. 131, No. 2, 2006, pp. 461-469. doi:10.1053/j.gastro.2006.05.021
[29] S. N. Goldberg, C. J. Grassi, J. F. Cardella, Society of Interventional Radiology Technology Assessment Committee and the International Working Group on ImageGuided Tumor Ablation, “Image Guided Tumor Ablation: Standardization of Terminology and Reporting Criteria,” Journal of Vascular and Interventional Radiology, Vol. 20, No. 7, 2009, pp. S377-S390. doi:10.1016/j.jvir.2009.04.011
[30] M. Varela, M. I. Real, M. Burrel, et al., “Chemoembolization of Hepatocellular Carcinoma with Drug Eluting Beads: Efficacy and Doxorubicin Pharmacokinetics,” Journal of Hepatology, Vol. 46, No. 3, 2007, pp. 474-481. doi:10.1016/j.jhep.2006.10.020
[31] J. L. Raoul, D. Guyader, J. F. Bretagne, et al., “Prospective Randomized Trial of Chemoembolization versus Intraarterial Injection of 131I-Labeled-Iodized Oil in the Treatment of Hepatocellular Carcinoma,” Hepatology, Vol. 26, No. 5, 1997, pp. 1156-1161.
[32] R. Salem, R. J. Lewandowski, M. F. Mulcahy, et al., “Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of LongTerm Outcomes,” Gastroenterology, Vol. 138, No. 1, 2010, pp. 52-64. doi:10.1053/j.gastro.2009.09.006
[33] L. M. Kulik, B. I. Carr, M. F. Mulcahy, et al., “Safety and Efficacy of 90Y Radiotherapy for Hepatocellular Carcinoma with and without Portal Vein Thrombosis,” Hepatology, Vol. 47, No. 1, 2008, pp. 71-81. doi:10.1002/hep.21980
[34] B. I. Carr, “Some New Approaches to the Management of Hepatocellular Carcinoma,” Seminars in Oncology, Vol. 39, No. 4, 2012, pp. 369-373. doi:10.1053/j.seminoncol.2012.05.007
[35] R. S. Finn, “Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?” Clinical Cancer Research, Vol. 16, No. 2, 2010, pp. 390-397. doi:10.1158/1078-0432.CCR-09-2084
[36] C. Frenette and R. Gish, “Targeted Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives, Challenges and Implications,” World Journal of Gastroenterology, Vol. 18, No. 6, 2012, pp. 498-506. doi:10.3748/wjg.v18.i6.498
[37] M. Cervello, J. A. McCubrey, A. Cusimano, et al., “Targeted Therapy for Hepatocellular Carcinoma: Novel Agents on the Horizon,” Oncotarget, Vol. 3, No. 3, 2012, pp. 236-260.
[38] K. E. O’Reilly, F. Rojo, Q. B. She, et al., “mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt,” Cancer Research, Vol. 66, No. 3, 2006, pp. 1500-1508. doi:10.1158/0008-5472.CAN-05-2925
[39] A. Forner, J. M. Llovet and J. Bruix, “Hepatocellular Carcinoma,” Lancet, Vol. 379, No. 9822, 2012, pp. 1245-1255. doi:10.1016/S0140-6736(11)61347-0
[40] S. M. Wilhelm, C. Carter, L. Tang, et al., “BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis,” Cancer Research, Vol. 64, No. 19, 2004, pp. 7099-7109. doi:10.1158/0008-5472.CAN-04-1443
[41] Y. S. Chang, J. Adnane, P. A. Trail, et al., “Sorafenib (BAY 43-9006) Inhibits Tumor Growth and Vascularization and Induces Tumor Apoptosis and Hypoxia in RCC Xenograft Models,” Cancer Chemotherapy and Pharmacology, Vol. 59, No. 5, 2007, pp. 561-574. doi:10.1007/s00280-006-0393-4
[42] European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, “EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma,” Journal of Hepatology, Vol. 56, No. 4, 2012, pp. 908-943.
[43] J. M. Llovet, S. Ricci, V. Mazzaferro, et al., “SHARP Investigators Study Group. Sorafenib in Advanced Hepatocellular Carcinoma,” The New England Journal of Medicine, Vol. 359, No. 4, 2008, pp. 378-390. doi:10.1056/NEJMoa0708857
[44] A. L. Cheng, Y. K. Kang, Z. Chen, et al., “Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial,” The Lancet Oncology, Vol. 10, No. 1, 2009, pp. 25-34. doi:10.1016/S1470-2045(08)70285-7
[45] H. Y. Woo, J. Heo, K. T. Yoon, et al., “Clinical Course of Sorafenib Treatment in Patients with Hepatocellular Carcinoma,” Scandinavian Journal of Gastroenterology, Vol. 47, No. 7, 2012, pp. 809-819. doi:10.3109/00365521.2012.683040
[46] B. Xie, D. H. Wang and S. J. Spechler, “Sorafenib for Treatment of Hepatocellular Carcinoma: A Systematic Review,” Digestive Diseases and Sciences, Vol. 57, No. 5, 2012, pp. 1122-1129. doi:10.1007/s10620-012-2136-1
[47] K. Nojiri, K. Sugimoto, K. Shiraki, et al., “Sorafenib and TRAIL Have Synergistic Effect on Hepatocellular Carcinoma,” International Journal of Oncology, Vol. 42, No. 1, 2013, pp. 101-108.
[48] A. Vitale, G. Lombardi, R. Ramirez Morales, et al., “Potential Impact of Sorafenib on the Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma,” Digestive and Liver Disease, Vol. 44, No. 5, 2012, pp. 361-362. doi:10.1016/j.dld.2012.02.014
[49] A. Weinmann, I. M. Niederle, S. Koch, et al., “Sorafenib for Recurrence of Hepatocellular Carcinoma after Liver Transplantation,” Digestive and Liver Disease, Vol. 44, No. 5, 2012, pp. 432-437. doi:10.1016/j.dld.2011.12.009
[50] S. Hagiwara, M. Kudo, T. Nagai, et al., “Activation of JNK and High Expression Level of CD133 Predict a Poor Response to Sorafenib in Hepatocellular Carcinoma,” British Journal of Cancer, Vol. 106, No. 12, 2012, pp. 1997-2003. doi:10.1038/bjc.2012.145
[51] S. L. Chan, T. Mok and B. B. Ma, “Management of Hepatocellular Carcinoma: Beyond Sorafenib,” Current Oncology Reports, Vol. 14, No. 3, 2012, pp. 257-266. doi:10.1007/s11912-012-0233-0
[52] A. Cheng, Y. Kang, D. Lin, et al., “Phase III Trial of Sunitinib (Su) versus Sorafenib (So) in Advanced Hepatocellular Carcinoma (HCC),” Journal of Clinical Oncology, Vol. 29, No. 15, 2011, p. 4000.
[53] R. S. Finn, Y. K. Kang, M. Mulcahy, et al., “Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma,” Clinical Cancer Research, Vol. 18, No. 7, 2012, pp. 2090-2098. doi:10.1158/1078-0432.CCR-11-1991
[54] J. A. Garcia and L. R. Roberts, “Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma,” Journal of Hepatology, Vol. 56, No. 2, 2012, pp. 486-487. doi:10.1016/j.jhep.2011.07.033
[55] J. W. Park, R. S. Finn, J. S. Kim, et al., “Phase II, OpenLabel Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma,” Clinical Cancer Research, Vol. 17, No. 7, 2011, pp. 1973-1983. doi:10.1158/1078-0432.CCR-10-2011
[56] H. C. Toh, P. J. Chen, B. I. Carr, et al., “Phase 2 Trial of Linifanib (ABT-869) in Patients with Unresectable or Metastatic Hepatocellular Carcinoma,” Cancer, Vol. 119, No. 2, 2012, pp. 380-387. doi:10.1002/cncr.27758
[57] W. T. Tai, A. L. Cheng, C. W. Shiau, et al., “Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3,” Molecular Cancer Therapeutics, Vol. 11, No. 2, 2012, pp. 452-463. doi:10.1158/1535-7163.MCT-11-0412
[58] K. F. Chen, H. L. Chen, C. Y. Liu, et al., “Dovitinib Sensitizes Hepatocellular Carcinoma Cells to TRAIL and Tigatuzumab, a Novel Anti-DR5 Antibody, through SHP-1-Dependent Inhibition of STAT3,” Biochemical Pharmacology, Vol. 83, No. 6, 2012, pp. 769-777. doi:10.1016/j.bcp.2011.12.035
[59] F. Kanai, H. Yoshida, R. Tateishi, et al., “A Phase I/II Trial of the Oral Antiangiogenic Agent TSU-68 in Patients with Advanced Hepatocellular Carcinoma,” Cancer Chemotherapy and Pharmacology, Vol. 67, No. 2, 2011, pp. 315-324. doi:10.1007/s00280-010-1320-2
[60] A. B. Siegel, E. I. Cohen, A. Ocean, et al., “Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma,” Journal of Clinical Oncology, Vol. 26, No. 18, 2008, pp. 2992-2998. doi:10.1200/JCO.2007.15.9947
[61] A. X. Zhu, R. S. Finn, M. F. Mulcahy, et al., “A Phase II Study of Ramucirumab as First-Line Monotherapy in Patients (pts) with Advanced Hepatocellular Carcinoma (HCC),” Journal of Clinical Oncology, Vol. 28, 2010.
[62] A. O. Kaseb, E. Garrett-Mayer, J. S. Morris, et al., “Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial,” Oncology, Vol. 82, No. 2, 2012, pp. 67-74. doi:10.1159/000335963
[63] C. Hsu, T. S. Yang, T. I. Huo, et al., “Vandetanib in Patients with Inoperable Hepatocellular Carcinoma: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study,” Journal of Hepatology, Vol. 56, No. 5, 2012, pp. 1097-1103. doi:10.1016/j.jhep.2011.12.013
[64] R. K. Ramanathan, C. P. Belani, D. A. Singh, et al., “A Phase II Study of Lapatinib in Patients with Advanced Biliary Tree and Hepatocellular Cancer,” Cancer Chemotherapy and Pharmacology, Vol. 64, No. 4, 2009, pp. 777-783. doi:10.1007/s00280-009-0927-7
[65] T. Bekaii-Saab, J. Markowitz, N. Prescott, et al., “A Multi-Institutional Phase II Study of the Efficacy and tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas,” Clinical Cancer Research, Vol. 15, No. 18, 2009, pp. 5895-5901. doi:10.1158/1078-0432.CCR-09-0465
[66] A. X. Zhu, K. Stuart, L. S. Blaszkowsky, et al., “Phase 2 Study of Cetuximab in Patients with Advanced Hepatocellular Carcinoma,” Cancer, Vol. 110, No. 3, 2007, pp. 581-589. doi:10.1002/cncr.22829
[67] Y. Gruenwald, L. Wilkens, M. Gebel, et al., “A Phase II Open-Label Study of Cetuximab in Unresectable Hepatocellular Carcinoma: Final Results,” ASCO Annual Meeting Proceedings, Vol. 25, No. 18S, 2007, p. 4598.
[68] A. X. Zhu, T. A. Abrams, R. Miksad, et al., “Phase 1/2 Study of Everolimus in Advanced Hepatocellular Carcinoma,” Cancer, Vol. 117, No. 22, 2011, pp. 5094-5102. doi:10.1002/cncr.26165
[69] P. Zucali, A. Santoro, C. Rodriguez-Lope, et al., “Final Results from ARQ 197-114: A Phase Ib Safety Trial Evaluating ARQ 197 in Cirrhotic Patients (pts) with Hepatocellular Carcinoma (HCC),” Journal of Clinical Oncology, Vol. 28, 2010, Abs 4137.
[70] C. Y. Yu, H. Y. Ou, T. L. Huang, et al., “Hepatocellular Carcinoma Downstaging in Liver Transplantation,” Transplantation Proceedings, Vol. 44, No. 2, 2012, pp. 412-414. doi:10.1016/j.transpro ceed.2012.01.043
[71] C. Tomuleasa, O. Soritau, A. Orza, et al., “Gold Nanoparticles Conjugated with Cisplatin/ Doxorubicin/Capecitabine Lower the Chemoresistance of Hepatocellular Carcinoma-Derived Cancer Cells,” Journal of Gastrointestinal and Liver Diseases, Vol. 21, No. 2, 2012, pp. 187-196.
[72] J. Ji and X. W. Wang, “Clinical Implications of Cancer Stem Cell Biology in Hepatocellular Carcinoma,” Seminars in Oncolog, Vol. 39, No. 4, 2012, pp. 461-472. doi:10.1053/j.seminoncol.2012.05.011
[73] Y. Sawada, T. Yoshikawa, D. Nobuoka, et al., “Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival,” Clinical Cancer Research, Vol. 18, No. 13, 2012, pp. 3686-3896. doi:10.1158/1078-0432.CCR-11-3044
[74] J. H. Zhong, L. Ma, L. C. Wu, et al., “Adoptive Immunotherapy for Postoperative Hepatocellular Carcinoma: A Systematic Review,” International Journal of Clinical Practic, Vol. 66, No. 1, 2012, pp. 21-27. doi:10.1111/j.1742-1241.2011.02814.x
[75] J. H. Zhong, H. Li, L. Q. Li, et al., “Adjuvant Therapy Options Following Curative Treatment of Hepatocellular Carcinoma: A Systematic Review of Randomized Trials,” European Journal of Surgical Oncology, Vol. 38, No. 4, 2012, pp. 286-295. doi:10.1016/j.ejso.2012.01.006
[76] D. Miki, H. Ochi, C. N. Hayes, et al., “Hepatocellular Carcinoma: Towards Personalized Medicine,” Cancer Science, Vol. 103, No. 5, 2012, pp. 846-850. doi:10.1111/j.1349-7006.2012.02242.x
[77] C. Della Corte and M. Colombo, “Surveillance for Hepatocellular Carcinoma,” Seminars in Oncology, Vol. 39, No. 4, 2012, pp. 384-398. doi:10.1053/j.seminoncol.2012.05.002
[78] R. Aghoram, P. Cai and J. A. Dickinson, “Alpha-Foetoprotein and/or Liver Ultrasonography for Screening of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B,” Cochrane Database of Systematic Reviews, Vol. 9, 2012, Article ID: CD002799.
[79] S. S. Lee, H. S. Shin, H. J. Kim, et al., “Analysis of Prognostic Factors and 5-Year Survival Rate in Patients with Hepatocellular Carcinoma: A Single-Center Experience,” Korean Journal of Hepatology, Vol. 18, No. 1, 2012, pp. 48-55. doi:10.3350/kjhep.2012.18.1.48
[80] T. Ochiai, H. Ikoma, Y. Murayama, et al., “Factors Resulting in 5-Year Disease-Free Survival after Resection of Hepatocellular Carcinoma,” Anticancer Research, Vol. 32, No. 4, 2012, pp. 1417-1422.
[81] A. M. Gluer, N. Cocco, J. M. Laurence, et al., “Systematic Review of Actual 10-Year Survival Following Resection for Hepatocellular Carcinoma,” HPB (Oxford), Vol. 14, No. 5, 2012, pp. 285-290. doi:10.1111/j.1477-2574.2012.00446.x

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.